Myelin Therapeutics

Myelin Therapeutics is generating a novel protein therapy that can trigger remyelination of dying neurons in pathologies associated to demyelination including Amyotrophic Lateral Sclerosis, Spinocerebellar Ataxias and Multiple Sclerosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://myelintherapeutics.webs.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
571 East New York Avenue, Suite 3D,, NY 11225
Brooklyn
United States
Email
Contact Number
+1 203-900-4928

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Myelin Therapeutics lead program uses AAV-mediated technology to deliver a natural protein to simulate an endogenous mechanisms of brain repair in genetically-inherited pathologies of the central and peripheral neurvous systems.